CytomX Therapeutics Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
122
- Stock Symbol
-
CTMX
- Investments
-
1
- Share Price
-
$1.23
- (As of Tuesday Closing)
CytomX Therapeutics General Information
Description
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Contact Information
Website
www.cytomx.comCorporate Office
- 151 Oyster Point Boulevard
- Suite 400
- South San Francisco, CA 94080
- United States
Corporate Office
- 151 Oyster Point Boulevard
- Suite 400
- South San Francisco, CA 94080
- United States
CytomX Therapeutics Stock Performance
As of 03-Dec-2024, CytomX Therapeutics’s stock price is $1.23. Its current market cap is $96.3M with 78.3M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.23 | $1.09 | $0.83 - $5.85 | $96.3M | 78.3M | 1.03M | $0.16 |
CytomX Therapeutics Financials Summary
As of 30-Sep-2024, CytomX Therapeutics has a trailing 12-month revenue of $127M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (33,257) | (75,222) | (69,539) | 68,766 |
| Revenue | 126,617 | 101,214 | 53,163 | 37,312 |
| EBITDA | 8,541 | (4,339) | (98,552) | (113,419) |
| Net Income | 13,830 | (569) | (99,317) | (115,870) |
| Total Assets | 138,981 | 201,792 | 260,891 | 339,411 |
| Total Debt | 10,597 | 13,974 | 18,057 | 21,674 |
CytomX Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CytomX Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
CytomX Therapeutics Comparisons
Industry
Financing
Details
CytomX Therapeutics Competitors (91)
One of CytomX Therapeutics’s 91 competitors is Mersana Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | ||||
| Vor Biopharma | Formerly VC-backed | Cambridge, MA | ||||
| Celldex Therapeutics | Formerly VC-backed | Hampton, NJ | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
CytomX Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CytomX Therapeutics Patents
CytomX Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230174995-A1 | Activatable polypeptide complex | Pending | 15-Oct-2021 | ||
| US-20230183382-A1 | Activatable polypeptide complex | Pending | 15-Oct-2021 | ||
| AU-2022365116-A1 | Activatable polypeptide complex | Pending | 15-Oct-2021 | ||
| AU-2022367525-A1 | Activatable polypeptide complex | Pending | 15-Oct-2021 | ||
| CA-3234609-A1 | Activatable polypeptide complex | Pending | 15-Oct-2021 | C07K16/2863 |
CytomX Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CytomX Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CytomX Therapeutics Investments (1)
CytomX Therapeutics’s most recent deal was a Corporate Asset Purchase with Agensys (Drug conjugate linker-toxin & CD3-based bispecific technologies). The deal was made on 07-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Agensys (Drug conjugate linker-toxin & CD3-based bispecific technologies) | 07-Jan-2019 | Corporate Asset Purchase | Buildings and Property |
CytomX Therapeutics ESG
Risk Overview
Risk Rating
Updated October, 01, 2023
27.28 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,035
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
CytomX Therapeutics FAQs
-
When was CytomX Therapeutics founded?
CytomX Therapeutics was founded in 2008.
-
Where is CytomX Therapeutics headquartered?
CytomX Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of CytomX Therapeutics?
CytomX Therapeutics has 122 total employees.
-
What industry is CytomX Therapeutics in?
CytomX Therapeutics’s primary industry is Biotechnology.
-
Is CytomX Therapeutics a private or public company?
CytomX Therapeutics is a Public company.
-
What is CytomX Therapeutics’s stock symbol?
The ticker symbol for CytomX Therapeutics is CTMX.
-
What is the current stock price of CytomX Therapeutics?
As of 03-Dec-2024 the stock price of CytomX Therapeutics is $1.23.
-
What is the current market cap of CytomX Therapeutics?
The current market capitalization of CytomX Therapeutics is $96.3M.
-
What is CytomX Therapeutics’s current revenue?
The trailing twelve month revenue for CytomX Therapeutics is $127M.
-
Who are CytomX Therapeutics’s competitors?
Mersana Therapeutics, Aura Biosciences, Vor Biopharma, Celldex Therapeutics, and Inovio Pharmaceuticals are some of the 91 competitors of CytomX Therapeutics.
-
What is CytomX Therapeutics’s annual earnings per share (EPS)?
CytomX Therapeutics’s EPS for 12 months was $0.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
